PhD Opportunity in Cancer Research: The University of Vienna is offering a PhD position in a project focused on studying and overcoming the H2O2-induced resistance towards epidermal growth factor receptor (EGFR) inhibitors in advanced non-small cell lung cancer (NSCLC). The research will utilize cutting-edge techniques in chemical biology, biochemistry, and molecular biology.
Designation
PhD Candidate in Pharmaceutical Sciences
Details
| Field | Details |
|---|---|
| Research Area | Cancer Chemical Biology, ChemoProteomics, Medicinal Chemistry |
| Location | University of Vienna, Austria |
| Eligibility/Qualification | Master’s degree (or equivalent) in Pharmaceutical Sciences, Biochemistry, Chemical Biology, or (Molecular) Biology. Experience in molecular biology, biochemistry, and/or chemical biology is preferred. Prior programming skills in Python and R are advantageous. |
| Description | This project will explore resistance mechanisms in NSCLC related to H2O2 signaling pathways, focusing on the development of new covalent inhibitors and utilizing advanced chemical biology methods. Key topics include genetic alterations, phenotypic plasticity, and posttranslational modifications. The position offers training at Ludwig Maximilian University (LMU) Munich for the first three months. |
| How to Apply | Interested candidates should send their application to vds.phanuspo@univie.ac.at along with a CV, motivation letter, and relevant academic documents. |
| Last Date to Apply | Applications are accepted until the position is filled. It is advisable to apply as soon as possible. |
This PhD position provides an exciting opportunity to contribute to groundbreaking research in cancer treatment and drug resistance mechanisms. Interested applicants are encouraged to apply promptly. For more detailed information, please visit Konrad Lab’s website or contact Ass.-Prof. Dr. David Benjamin Konrad at david.benjamin.konrad@univie.ac.at for specific project-related questions.
